Partner I Dr. sc. ETH, MSc ETH Chemie, Europäischer und Schweizer Patentanwalt, European Patent Litigator
-
„A potentially boring topic was made very interesting and easy to understand.”
-
„Rising star 2025”
-
„This was my first lecture at ETH, and I was so surprised by the expertise and motivation of the two lecturers. I had nothing to do with patents before, but it was explained so well that I really liked and understood the topic.”
-
„Rising star 2024”
-
„Even though I had very little interest in the beginning, the lecturers managed to get me interested and invested in the topic. Well done!”
Christian Ebner ist zugelassener Vertreter vor dem Europäischen Patentamt mit Schwerpunkt auf den Gebieten Chemie, Biotechnologie, Medizinaltechnik, Anlagenbau und Mechanik.
Christian Ebner studierte Chemie an der ETH Zürich und spezialisierte sich im Bereich der komplexen organischen Synthese. Nach seiner Master Thesis am Scripps Research Institute in La Jolla, USA, promovierte er am Laboratorium für Organische Chemie an der ETH Zürich. Die Schwerpunkte seiner Dissertation lagen auf den Gebieten der Naturstoffsynthese, Reaktionsentwicklung und der Synthese von bioaktiven Zielmolekülen. Christian Ebner ist seit Januar 2017 für RENTSCH PARTNER tätig.
Institut der beim Europäischen Patentamt zugelassenen Vertreter
Licensing Executives Society - Fachverein für Lizenzierung, Technologietransfer und Geistiges Eigentum
Verband der freiberuflichen Europäischen und Schweizer Patentanwälte (VESPA)
Verband Schweizerischer Patent- und Markenanwälte
- Medical devices and the exclusion from patentability
Mitteilungen der deutschen Patentanwälte - Heft 4|2024
19. November 2024 - Important Aspects of IP for Start-Ups: Strategies for Avoiding Common Pitfalls
In: Bader, M.A., Süzeroğlu-Melchiors, S. (eds) Intellectual Property Management for Start-ups. Management for Professionals. Springer, Cham., Februar 2023 (Link zum Buch)
09. March 2023 - Aktuelles aus der Schweiz
Mitteilungen der deutschen Patentanwälte - Heft 2|2023
09. February 2023 - Exhaustion of Method Patents in Switzerland: “Sell Someone an Inch and They’ll Take a Mile”?
Life Science Recht Nr. 4, 2022, S. 243-250 (Link zum Beitrag)
10. November 2022 - Challenges and Opportunities in Licensing Biotech-Research Tools
Life Science Recht Nr. 4, 2021, S. 199–207 (Link)
23. November 2021 - Medical Devices and the Exclusion from Patentability
Life Science Recht Nr. 2, 2021, S. 71–80 (Link)
23. November 2021 - Opinion G 3/19 of the Enlarged Board of Appeal
Life Science Recht Nr. 3, 2020, S. 168 ff.
27. November 2020 - The Concept of Plausibility in Patent Law
Life Science Recht Nr.1 2020, 45-51
26. March 2020 - Case Law of the Swiss Federal Patent Court in 2018
Life Science Recht Nr. 4, 2019, 262 ff.
06. November 2019 - Patentability of Plants after T 1063/18
sic! 2019, 7/8, S. 457 ff.
23. August 2019 - Genome Editing – Upcoming Challenges for Life Sciences Law
Life Science Recht Nr. 1, 2019, S. 64 ff.
06. February 2019 - Decision G 1/16 of the Enlarged Board of Appeal of the European Patent Office – Disclaimer III
sic! 2018, 500 ff.
13. September 2018 - Case Law of the Federal Patent Court – Selected Decisions in 2017
Life Science Recht Nr. 3, 2018, S. 213 ff.
17. July 2018
- Sell or Rent? Does it impact your intellectual property? Yes! It is a business decision which may strongly affect your IP06. March 2024
- The Members of the EU Parliament have agreed to adapt the rules for NGT plants (New Genomic Techniques, i.e. plants which have been obtained by genetic engineering tools, such as CRISPR/Cas). In their proposal, the MEPs aim to introduce a complete exclusion from patentability for all NGT plants. The intention behind seems to be to avoid legal uncertainties and dependencies for farmers and breeders.22. February 2024
- How can startups protect their inventions? Christian Ebner and Andrea Carreira tell the success story of a swiss startup.15. July 2020